Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study.
Pearce
Celeste L
CL
Department of Preventive Medicine and USC/Norris Comprehensive Cancer Center and Hospital, University of Southern California Keck School of Medicine, Los Angeles, California 90089-9176, USA.
Makridakis
Nick M
NM
Ross
Ronald K
RK
Pike
Malcolm C
MC
Kolonel
Laurence N
LN
Henderson
Brian E
BE
Reichardt
Juergen K V
JK
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000235:genetics*; D019943:Amino Acid Substitution; D016022:Case-Control Studies; D005006:Ethnicity; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D011110:Polymorphism, Genetic; D011471:Prostatic Neoplasms / Q000209:etiology / Q000235:genetics*; D012042:Registries; D012307:Risk Factors
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase